SARS-CoV-2 and COVID-19 Research

This study characterizes the molecular interfaces of the SARS-CoV-2 N protein's CTD and flanking IDRs, revealing their roles in oligomerization, RNA binding, and phase separation.

This paper identifies PA-001, a macrocyclic peptide that inhibits SARS-CoV-2 infection by targeting the S2 subunit's FPPR region, showing broad antiviral activity and efficacy in animal models and clinical trials.

The paper characterizes early vaccine-induced antibodies against SARS-CoV-2, showing some are broad and potent while others are more variant-sensitive.

This study quantifies how exposure route, rather than dose, influences SARS-CoV-2 infection kinetics in non-human primates using a large meta-analysis of challenge experiments.

This study identifies MED13 and DDX60 as critical host factors for SARS-CoV-2 infection through a haploid genetic screen in mouse cells.

This study shows TMPRSS2 reduces antibody binding to SARS-CoV-2 spike by altering its structure and shedding, but not virion infectivity.

The paper shows that mutations increasing ORF9b expression are common in SARS-CoV-2 variants and PCI sequences, suggesting ORF9b's role in viral evolution and immune evasion.

The paper examines how mutations in the HCoV-229E spike affect receptor binding and serum neutralization, revealing counterbalancing effects on these functions.

This study identifies an immunodominant S2 apex epitope in SARS-CoV-2 that elicits a public antibody clonotype, highlighting its role as a barrier to universal coronavirus vaccines.

The paper assesses neutralizing antibody responses to multiple coronaviruses in Wuhan population samples before and after the pandemic, finding enhanced cross-neutralizing activity against sarbecoviruses.

This paper develops a machine learning framework to predict human infection potential of coronaviruses using spike protein sequences, identifying motifs KIQ and LEP associated with human infection.

This study identifies SARS-CoV-2 neutralizing antibodies and rapid viral RNA degradation in white-tailed deer milk, revealing distinct antiviral mechanisms compared to human milk.

This study compares intranasal and intramuscular vaccines, finding that the intranasal Ad4-S vaccine provides more durable and effective immune responses against SARS-CoV-2 in preclinical models.

The paper identifies novel svRNA-triplex-forming oligonucleotides in SARS-CoV-2 and their evolutionary conservation and potential role in host adaptation and viral evolution.

This study develops domain-specific nanobodies that inhibit SARS-CoV-2 infection by disrupting N protein phase separation and replication.

This paper shows the SARS-CoV-2 N protein traffics to the cell surface via a ceramide-dependent pathway, independent of viral assembly, and reveals its role in immune responses.

This study compares the impact of SARS-CoV-2 variants on host cell RNA and RNA binding protein distribution, finding Omicron causes less disruption and maintains higher expression of translation factors.

This study vaccinates nonhuman primates with SARS-CoV-2 and MERS-CoV spike proteins to elicit cross-reactive antibodies that neutralize both sarbecoviruses and merbecoviruses.

This study investigates the biogenesis of the SARS-CoV-2 M protein, revealing key steps in its insertion, folding, and oligomerization.

This study uses ultra-deep sequencing to analyze intra-host SARS-CoV-2 diversity and co-infection-driven evolution in Chilean patients, finding increased genetic diversity and positive selection in the Spike gene during co-infections.

This study develops a mechanistic model of viral and antibody dynamics in non-human primates to quantify correlates of protection against SARS-CoV-2 infection.

This study develops a dual-chimeric virus to safely study antiviral resistance and cross-resistance using spike and protease inhibitors.

This study identifies two potent nanobodies targeting the conserved S2 region of SARS-CoV-2 spike protein that resist viral escape and reduce viral load in a hamster model.

The paper introduces a method to analyze antibody repertoires against a large library of SARS-CoV-2 RBD variants, revealing poly-specificity and immune constraints in vaccination responses.

This paper develops ARCADE, a high-throughput assay to profile antiviral antibody responses, showing mRNA vaccines elicit broader and stronger responses than adenovirus vector vaccines.

This study uses cryo-electron tomography to show temperature and receptor binding coordinate spike protein activation in HCoV-229E virions, revealing structural dynamics and conformational changes.

This paper develops a fluorescently labeled coronavirus by tagging the M protein with GFP to study intracellular trafficking and egress in live cells.

This study identifies NSP15 as a SARS-CoV-2 protein that interacts with host keratin type II cytoskeletal 1, leading to cytoskeletal collapse and reduced cell viability in Vero E6 cells.

This paper shows that combining Auranofin and Remdesivir synergistically inhibits SARS-CoV-2 in vitro and in animal models.